Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Single-center experience with the thoratec ventricular assist device.

R Körfer1, A El-Banayosy, L Arusoglu

  • 1Department of Thoracic and Cardiovascular Surgery, Heart Center North Rhine-Westphalia, Ruhr University of Bochum, Bad Oeynhausen, Germany.

The Journal of Thoracic and Cardiovascular Surgery
|March 1, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Total Artificial Heart Implantation Blood Pressure Management as Resolving Treatment for Massive Hemolysis following Total Artificial Heart Implantation.

The heart surgery forum·2016
Same author

[INR Self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial)].

Zeitschrift fur Kardiologie·2014
Same author

Successful treatment of peripartum cardiomyopathy with extracorporeal membrane oxygenation.

Perfusion·2009
Same author

Implantation of CardioWest total artificial heart for irreversible acute myocardial infarction shock.

The heart surgery forum·2007
Same author

A risk score to predict 30-day mortality in patients with intra-aortic balloon pump implantation.

The Thoracic and cardiovascular surgeon·2007
Same author

IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support.

Journal of thrombosis and haemostasis : JTH·2006

The Thoratec ventricular assist device is a reliable option for heart support, particularly as a bridge to transplantation. While effective, complications like bleeding and organ failure require further study for improved patient outcomes.

Area of Science:

  • Cardiovascular Surgery
  • Medical Devices
  • Transplantation Medicine

Background:

  • The Thoratec ventricular assist device is widely used for univentricular and biventricular cardiac support.
  • Experience with over 100 patient implantations provides valuable insights into its efficacy and challenges.

Purpose of the Study:

  • To describe the clinical experience with the Thoratec ventricular assist device in a large patient cohort.
  • To evaluate the device's performance in bridge-to-transplant and cardiogenic shock scenarios.

Main Methods:

  • A retrospective analysis of 114 patients who received the Thoratec ventricular assist device between March 1992 and June 1998.
  • Patients were categorized into three groups: bridge-to-transplant (n=84), postcardiotomy cardiogenic shock (n=17), and other cardiogenic shock (n=13).

Related Experiment Videos

Main Results:

  • Bridge-to-transplant survival to transplantation was 68%, with 88% posttransplant survival. Age over 60 was the sole independent risk factor for survival.
  • Survival rates for postcardiotomy cardiogenic shock and other causes were 47% and 31%, respectively.
  • Common complications included bleeding, multiple organ failure, liver failure, sepsis, and neurologic disorders.

Conclusions:

  • The Thoratec ventricular assist device demonstrates reliability for bridge-to-transplant and postcardiotomy support.
  • Further research is needed to optimize patient selection and management strategies to mitigate complications.